Form 4: Anika Therapeutics Director Stephen Richard Receives Significant RSU Grant

Anika Therapeutics, Inc. Director Stephen Richard was granted 14,164 restricted stock units, increasing his beneficial ownership to 47,871 shares.

Summary

• Stephen Richard, a Director at Anika Therapeutics, Inc. (ANIK), acquired 14,164 shares of common stock on June 20, 2025.
• These shares are in the form of Restricted Stock Units (RSUs), which represent a contingent right to receive one share of the company's common stock per RSU.
• The RSUs were granted at a price of $0, indicating they are part of an equity compensation plan.
• Following this transaction, Mr. Richard's direct beneficial ownership in Anika Therapeutics, Inc. increased to 47,871 shares.
• The RSUs are scheduled to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of alignment between management and shareholders, and a routine compensation event. It doesn't indicate any negative operational or financial news.

Positives

• The grant of 14,164 Restricted Stock Units (RSUs) to Director Stephen Richard aligns his interests with long-term shareholder value, as the value of these units is tied to the company's stock performance.
• The increase in beneficial ownership to 47,871 shares demonstrates continued commitment and confidence from a key board member in the company's future.

Negatives

• The grant of RSUs at a $0 price represents dilution potential for existing shareholders upon vesting, although this is a standard practice for equity compensation.

Risks

• The value of the granted RSUs is subject to the future performance of Anika Therapeutics' common stock, meaning the actual value realized by the director could be lower if the stock price declines.
• The vesting of RSUs is contingent on future dates (earlier of 2026 annual meeting or June 20, 2026), introducing a time-based risk for the recipient.

Future Outlook

The document indicates a future vesting event for the 14,164 Restricted Stock Units (RSUs) granted to Director Stephen Richard, which are set to vest in full on the earlier of the 2026 annual meeting of stockholders or June 20, 2026.

Industry Context

This RSU grant is a standard practice in the biotechnology and medical device industry for compensating directors and aligning their interests with long-term company performance, reflecting common corporate governance practices for executive and board remuneration.

Corporate Governance

Related Party Transactions

• The grant of 14,164 Restricted Stock Units (RSUs) to Stephen Richard, a director of Anika Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the compensation is tied to the company's stock performance. However, it also represents potential future dilution upon vesting.
• Employees: No direct impact on employees is indicated by this specific filing, though equity compensation plans are common across all levels of a company.

Next Steps

• The 14,164 Restricted Stock Units (RSUs) granted to Stephen Richard are expected to vest in full on the earlier of the 2026 annual meeting of Anika Therapeutics' stockholders or June 20, 2026.

Key Dates

Keywords

Anika Therapeutics, ANIK, SEC Form 4, Restricted Stock Units, RSU, Beneficial Ownership, Director Compensation, Equity Grant, Insider Trading, Corporate Governance